Statement of Principles concerning malignant melanoma of the skin (Reasonable Hypothesis) (No. 102 of 2015)

Administered by Department of Veterans' Affairs

Legislation au F2015L01317 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 102 of 2015

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), revokes Instrument No. 79 of 2007, determined under subsection 196B(2) of the VEA concerning malignant melanoma of the skin.
  2. The Authority is of the view that there is sound medical-scientific evidence that indicates that malignant melanoma of the skin and death from malignant melanoma of the skin can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning malignant melanoma of the skin (Reasonable Hypothesis) (No. 102 of 2015).  This Instrument will in effect replace the revoked Statement of Principles.

Purpose and Operation

3.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

4.             The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting malignant melanoma of the skin or death from malignant melanoma of the skin, with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 31 October 2012 concerning malignant melanoma of the skin in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • revising the definition of 'malignant melanoma of the skin' in subsection 7(2);
  • revising the factor in subsection 9(1) concerning 'sunburn';
  • revising the factor in subsection 9(2) concerning 'sunlight or ultraviolent light exposure';
  • new factor in subsection 9(3) concerning 'ultraviolet radiation exposure from an ultraviolet-emitting tanning device';
  • new factor in subsection 9(4) concerning 'solid organ or bone marrow transplantation';
  • revising the factor in subsection 9(5) concerning 'an immunosuppressive drug';
  • revising the factor in subsection 9(7) concerning 'human immunodeficiency virus';
  • new factor in subsection 9(8) concerning 'non-Hodgkin's lymphoma or chronic lymphocytic leukaemia/small cell lymphoma';
  • new factor in subsection 9(9) concerning 'Parkinson's disease';
  • new factor in subsection 9(10) concerning 'a scar involving the affected site, where the scar is the result of a thermal or chemical burn';
  • new definitions of 'equivalent sunlight exposure in other latitude zones', 'MRCA', 'sunburn as specified', 'tropical area', 'unprotected skin' and 'VEA' in Schedule 1 - Dictionary;
  • revising the definitions of 'immunosuppressive drug' and 'relevant service' in Schedule 1 - Dictionary; and
  • deleting the definitions of 'solar UV exposure factor ratio', 'solar UV exposure factor ratio formula' and 'sunburn'.

Consultation

7.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to malignant melanoma of the skin in the Government Notices Gazette of 31 October 2012, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

Human Rights

8.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

9.             The determining of this Instrument finalises the investigation in relation to malignant melanoma of the skin as advertised in the Government Notices Gazette of 31 October 2012.

References

10.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 102 of 2015

Kind of Injury, Disease or Death: Malignant melanoma of the skin

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant melanoma of the skin;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting malignant melanoma of the skin with the circumstances of eligible service rendered by a person, as set out in clause 4 of the Explanatory Notes;
  • replaces Instrument No. 79 of 2007; and
  • reflects developments in the available sound medical-scientific evidence concerning malignant melanoma of the skin which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 102 of 2015, made under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA), was enacted to address the need for updated and comprehensive medical-scientific evidence regarding the connection between malignant melanoma of the skin and specific military service conditions. The Authority determined that there is sufficient evidence to establish a reasonable hypothesis linking malignant melanoma of the skin to particular military services, thus revoking the previous Statement of Principles No. 79 of 2007. This new Statement of Principles outlines the minimum factors that must exist and be related to specified military services to support a claim under the VEA or MRCA. The Authority's decision is based on a thorough examination of the latest available medical-scientific evidence, and it aims to facilitate the assessment and review of claims related to malignant melanoma of the skin among eligible veterans and service personnel. The instrument also ensures compatibility with human rights, promoting veterans' rights to social security, adequate living standards, and health.

Scope and Application

The Repatriation Medical Authority Instrument No. 102 of 2015, concerning malignant melanoma of the skin, applies to individuals who have served in the Australian Defence Force and are making claims under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The Instrument specifies the circumstances under which service-related malignant melanoma of the skin can be recognised, thereby facilitating the process of claim assessment and the provision of compensation. The Instrument is applicable nationally across Australia, and its reach extends to all veterans and current or former Defence Force members who are seeking benefits related to malignant melanoma of the skin. The Instrument outlines the factors that must exist to establish a reasonable hypothesis connecting the disease with specific types of service, including operational, peacekeeping, and hazardous service, among others. The Instrument replaces an earlier Instrument No. 79 of 2007 and incorporates updated medical-scientific evidence. The Instrument does not specify any exclusions or exemptions, but its application may be subject to the criteria outlined within the Instrument itself. This Legislative Instrument is designed to be technically sound and to improve the quality of medico-scientific outcomes in the assessment and determination of benefits under the relevant Acts.

Key Provisions

The Repatriation Medical Authority Instrument No. 102 of 2015 primarily concerns the replacement of the previous Statement of Principles concerning malignant melanoma of the skin (Instrument No. 79 of 2007) under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). This new instrument sets out the factors that must exist to establish a reasonable hypothesis connecting malignant melanoma of the skin or death from malignant melanoma of the skin with specific types of service (Section 4). These types of service include operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. The Act imposes obligations on claimants and the Repatriation Commission to ensure that the claims are assessed in accordance with the newly established Statement of Principles. Claimants must provide evidence that links their malignant melanoma of the skin to the specified service, while the Repatriation Commission must evaluate these claims based on the minimum factors outlined in the Instrument (Section 4). This ensures that the claims process is thorough and that only those who meet the specified criteria can receive compensation or medical treatment. There are no explicit offences, penalties, or civil/criminal consequences mentioned for breaches of this Instrument. However, any failure to comply with the requirements for claiming under the VEA or MRCA could potentially lead to the denial of benefits or compensation. The primary focus of the Instrument is to establish clear criteria for assessing claims related to malignant melanoma of the skin, ensuring that claimants and the Repatriation Commission adhere to these criteria to facilitate accurate and fair assessments.

Legal classification tags

Area of Law
Veterans' Law
Health Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Consultation Requirements
Compliance Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.